Philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in those markets to build defensible, strong, and long-term businesses.
build portfolio among attractive life science sectors in a manner that balances risk while maximizing potential synergies and ultimate returns. Our focus is on opportunities in biotechnology, medical devices, and diagnostics, but we are continually responsive to the best areas for investing in order to adapt to changing market conditions.
Invest in companies that:
* are pursuing substantial and growing market opportunities * possess a unique and proprietary technology, with a clear competitive advantage * are early-stage opportunities * have or will attract strong management * have a strong investment syndicate * offer a defined path to liquidity
|Siluria Technologies||7/12||Series C||$30M||9|
|Siluria Technologies||9/11||Series B||$20M||7|
|Kythera Biopharmaceuticals||9/11||Series D||$37.4M||7|
|Constellation Pharmaceuticals||6/11||Series B||$15M||5|
|Siluria Technologies||10/10||Venture Round||$13.3M||6|
|Constellation Pharmaceuticals||6/10||Series B||$4.8M||5|
|Cambrios Technologies||11/09||Series D||$14.5M||14|
|Constellation Pharmaceuticals||8/09||Series B||$17.2M||4|
|Limerick BioPharma||7/09||Series C||$15M||3|
|Limerick BioPharma||6/08||Venture Round||$15.2M||3|
|Kythera Biopharmaceuticals||5/08||Series C||$30M||9|
|Kythera Biopharmaceuticals||7/06||Series B||$30M||6|